Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kodiak Sciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KOD
Nasdaq
8731
https://kodiak.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kodiak Sciences Inc
Q4 2023 Kodiak Sciences Inc Earnings Call
- Mar 29th, 2024 2:36 pm
Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results
- Mar 28th, 2024 12:32 pm
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Mar 28th, 2024 10:30 am
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
- Mar 26th, 2024 10:15 am
Following a 25% decline over last year, recent gains may please Kodiak Sciences Inc. (NASDAQ:KOD) institutional owners
- Feb 12th, 2024 11:03 am
Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B
- Feb 6th, 2024 3:49 pm
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
- Jan 30th, 2024 11:30 am
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2024 9:15 pm
Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?
- Dec 14th, 2023 4:30 pm
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
- Nov 21st, 2023 9:15 pm
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
- Nov 15th, 2023 1:00 pm
Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ...
- Nov 14th, 2023 11:09 pm
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
- Nov 14th, 2023 9:01 pm
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission
- Nov 6th, 2023 10:00 am
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
- Nov 3rd, 2023 11:54 am
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING
- Nov 2nd, 2023 3:21 am
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
- Oct 11th, 2023 10:00 am
Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound?
- Sep 13th, 2023 3:30 pm
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- Sep 8th, 2023 10:00 am
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion
- Sep 7th, 2023 10:00 am
Scroll